Key result
Ranolazine therapy at per day induced reversible myoclonus in a 72-year-old female with angina, which recurred upon rechallenge.
Case Report (n=1)
Ranolazine may cause reversible myoclonus, as demonstrated by a positive dechallenge and rechallenge in a single patient.
Answers are grounded in this paper and cite their sources.
Ranolazine may be associated with reversible myoclonus; single case report leaves open causality and incidence.
Myoclonus is not a known side effect of ranolazine. We report a case of myoclonus in a 72-year-old female who underwent cardiac catheterization for angina and was started on ranolazine after the procedure. Two days after ranolazine therapy on 1000 mg per day in divided doses, myoclonus developed, which severely impaired her normal activity. Her symptoms resolved 2 days after discontinuation of ranolazine. Ranolazine was resumed after discharge from hospital with recurrent myoclonus after two days of therapy. The causal relationship between ranolazine and myoclonus was suggested by cessation of myoclonus after ranolazine was discontinued.
No takes yet. Share an insight, caveat, or question.
Porhomayon et al. (2013) conducted a case report in Angina (n=1). Ranolazine was evaluated on Development of myoclonus. Ranolazine therapy at per day induced reversible myoclonus in a 72-year-old female with angina, which recurred upon rechallenge.
Synapse has enriched 10 related papers. Consider them for comparative context: